Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Fleming, Catherine A ^a,c,d   Tumilty, Sheila ^a   Murray, Jessica E ^b   Nunes, David ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG TOLERABILITY; EVALUATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA HEMORRHAGE; SIDE EFFECT; VIROLOGY;

BOSTON; COHORT STUDIES; DELIVERY OF HEALTH CARE, INTEGRATED; DEMOGRAPHY; ELIGIBILITY DETERMINATION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; OUTPATIENT CLINICS, HOSPITAL; TREATMENT OUTCOME;

EID: 16844370262     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427452     Document Type: Conference Paper

References (26)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
3. Murrill CS, Weeks S, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 2002; 92:385-7.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
6. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-22, 2002). Gastroenterology 2002; 123:2082-99.
7. Chung R, Anderson J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
8. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-8.
9. Mir J, Fleming C, Nunes D, Steger K, Koziel M, Craven D. Prevalence of hepatitis C virus in HIV-infected patients at Boston Medical Center: a case-control study [abstract 287]. In: Program and abstracts of the 36th annual meeting of the Infectious Diseases Society of America (Denver). Alexandria, VA: Infectious Diseases Society of America, 1998:89.
10. Fleming C, Nunes D, Christiansen D, et al. Predictors of liver disease and death in an urban cohort of HIV-infected patients [abstract 592]. In: Program and abstracts of the 41st annual meeting of the Infectious Disease Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2003:94.
11. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
12. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1039-46.
13. Mark K, Murray P, Callahan D, Gunn R. Follow-up of patients diagnosed with hepatitis C through STD clinic and HIV testsite screening program - San Diego CA 1999-2003 [abstract 602]. In: Program and abstracts of the 41st annual meeting of the Infectious Disease Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2003:127.
14. Talwanir P, Horvath J, Postik B. The role funding plays in the low treatment rates of hepatitis C among HIV-coinfected patients [abstract 596]. In: Program and abstracts of the 41st annual meeting of the Infectious Disease Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2003:125.
15. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93.
16. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
17. Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26(Suppl 1):39S-42S.
18. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36:242-52.
19. Zdilar D, Franco-Bronson K, Buchler K, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-11.
20. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63:194-8.
21. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-51.
22. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89-94.
23. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-92.
24. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(Suppl 1):112S-21S.
25. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001; 345:375-6.
26. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112:805-11.